These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 30116283)

  • 21. PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
    Gonçalves A; Bertucci A; Bertucci F
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
    Ratta R; Guida A; Scotté F; Neuzillet Y; Teillet AB; Lebret T; Beuzeboc P
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):549-560. PubMed ID: 32367009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    Boussios S; Moschetta M; Karihtala P; Samartzis EP; Sheriff M; Pappas-Gogos G; Ozturk MA; Uccello M; Karathanasi A; Tringos M; Rassy E; Pavlidis N
    Ann Transl Med; 2020 Dec; 8(24):1706. PubMed ID: 33490218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
    Boussios S; Karihtala P; Moschetta M; Karathanasi A; Sadauskaite A; Rassy E; Pavlidis N
    Diagnostics (Basel); 2019 Aug; 9(3):. PubMed ID: 31374917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
    Reinbolt RE; Hays JL
    Front Oncol; 2013 Oct; 3():237. PubMed ID: 24098868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
    Ziadeh T; Kourie HR
    Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
    Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
    Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
    Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review on mechanisms of resistance to PARP inhibitors.
    Desai C; Pathak A; Limaye S; Maniar V; Joshi A
    Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in cancer therapy using PARP inhibitors.
    Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
    Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
    Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of PARP inhibitors in
    Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
    Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
    J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PARP Inhibition and Beyond in BRCA-Associated Breast Cancer in Women: A State-Of-The-Art Summary of Preclinical Research on Risk Reduction and Clinical Benefits.
    Pauwels EKJ; Bourguignon MH
    Med Princ Pract; 2022; 31(4):303-312. PubMed ID: 35636395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer.
    Shen K; Yang L; Li FY; Zhang F; Ding LL; Yang J; Lu J; Wang NN; Wang Y
    Curr Drug Targets; 2022; 23(2):145-155. PubMed ID: 34139979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.